Press Releases

Press Releases

November 19, 2018
Less Than 90 days to FDA Action Date for Jeuveau IRVINE, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the conditional acceptance from the U.S. Food and Drug Administration (“FDA”) of the Jeuveau™ brand name for
November 5, 2018
- Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET - IRVINE, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported
November 1, 2018
IRVINE, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in two upcoming investor conferences. Event : Stifel 2018 Healthcare Conference Format: Presentation & 1x1
October 22, 2018
Appoints Kurt Knab as Vice President, Sales Appoints Alejandro “Alex” Sabad as Vice President, Operations Appoints Amy Marinne Fox as Vice President, Human Resources IRVINE, Calif. , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today
September 20, 2018

IRVINE, Calif. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will present at the Cantor Global Healthcare Conference in New York, NY .   Event: Cantor Global Healthcare Conference   Date:

August 29, 2018

Application Designated as Class 2 by U.S. FDA and Assigned February 2, 2019 PDUFA Date IRVINE, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the acceptance of its resubmission of its Biologics License Application

August 17, 2018

IRVINE, Calif. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines

Displaying 1 - 10 of 34